<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416949</url>
  </required_header>
  <id_info>
    <org_study_id>J0628</org_study_id>
    <secondary_id>CDR0000522716</secondary_id>
    <secondary_id>R01CA116477-01A1</secondary_id>
    <secondary_id>NA_00002264</secondary_id>
    <nct_id>NCT00416949</nct_id>
  </id_info>
  <brief_title>Iodine I 131 in Treating Patients With Thyroid Cancer</brief_title>
  <official_title>Dose-Response in Radionuclide Therapy of Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radioactive iodine kills thyroid cancer cells by giving off radiation.

      PURPOSE: This clinical trial is studying the side effects, best dose, and how well iodine I
      131 works in treating patients with thyroid cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the relationship between estimated absorbed dose of iodine I 131 and tumor
           response or normal organ toxicity for different dosimetric measures, using data derived
           from clinical radionuclide therapy studies in patients with thyroid cancer.

      OUTLINE: Patients receive oral dosimetric iodine I 131 (^131I) on day 2 and then undergo
      nuclear medicine imaging at 0.5-4 hours, 24, 48, and 72 hours after dosimetric ^131I.
      Single-photon emission computed tomography (SPECT)/CT scans are performed at 0.5-4 hours and
      24 or 48 hours over the head and neck region, including the salivary glands. Subsequent
      SPECT/CT scans are performed over the candidate tumor sites. Patients undergo ^131I therapy
      on day 11.

      Saliva is collected on days 1 and 2, weeks 2 and 4, and months 3 and 6 to measure saliva flow
      rate. Blood is collected at baseline and periodically during study to measure FLT3 ligand
      levels.

      PROJECTED ACCRUAL: A total of 96 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to loss of funding.
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Absorbed Dose</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Tumor absorbed doses (Gy) calculated using patient-specific dosimetry.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Patient-specific 3D-RD Dosimetry</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applied a patient-specific dosimetry calculation method to the imaging data collected to calculate tumor absorbed doses, using 3D-RD method.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patient-specific dosimetry</intervention_name>
    <description>Patient-specific 3D-RD dosimetry was applied to the data collected</description>
    <arm_group_label>Patient-specific 3D-RD Dosimetry</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of thyroid cancer

          -  Measurable disease by CT scan or nuclear medicine imaging

          -  Eligible, by standard of care criteria, for iodine I 131 therapy

        PATIENT CHARACTERISTICS:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective non-barrier method contraception (e.g., combined
             or progesterone-only oral contraceptive pill, intrauterine device, depot progesterone,
             or stable relationship with a partner who has had a vasectomy)

          -  No other malignancy within the past 5 years except squamous cell or basal cell
             carcinoma of the skin

          -  No nonthyroidal conditions known to affect iodine I 131 uptake (e.g., New York Heart
             Association class III or IV congestive heart failure or renal failure)

          -  No alcoholism or drug abuse within the past 2 years

          -  No severe emotional, behavioral, or psychiatric problems that would preclude study
             compliance (e.g., severe claustrophobia)

        PRIOR CONCURRENT THERAPY:

          -  No intravenous water-soluble radiographic contrast within the past 4 weeks

          -  No iodinated contrast agent within the past 3 months

          -  No concurrent drugs that may affect thyroid or renal function (e.g., renal drugs,
             lithium, amiodarone, other iodine-containing medication, or corticosteroids)

          -  No other concurrent investigational drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Sgouros, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <results_first_submitted>May 2, 2017</results_first_submitted>
  <results_first_submitted_qc>June 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 18, 2018</results_first_posted>
  <last_update_submitted>June 22, 2018</last_update_submitted>
  <last_update_submitted_qc>June 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anaplastic thyroid cancer</keyword>
  <keyword>insular thyroid cancer</keyword>
  <keyword>thyroid gland medullary carcinoma</keyword>
  <keyword>recurrent thyroid cancer</keyword>
  <keyword>stage I follicular thyroid cancer</keyword>
  <keyword>stage I papillary thyroid cancer</keyword>
  <keyword>stage II follicular thyroid cancer</keyword>
  <keyword>stage II papillary thyroid cancer</keyword>
  <keyword>stage III follicular thyroid cancer</keyword>
  <keyword>stage III papillary thyroid cancer</keyword>
  <keyword>stage IVA follicular thyroid cancer</keyword>
  <keyword>stage IVB follicular thyroid cancer</keyword>
  <keyword>stage IVC follicular thyroid cancer</keyword>
  <keyword>stage IVA papillary thyroid cancer</keyword>
  <keyword>stage IVB papillary thyroid cancer</keyword>
  <keyword>stage IVC papillary thyroid cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patient-specific 3D-RD Dosimetry</title>
          <description>Applied a patient-specific dosimetry calculation method to the imaging data collected to calculate tumor absorbed doses, using 3D-RD method.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patients refused to participate</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patient-specific 3D-RD Dosimetry</title>
          <description>Applied a patient-specific dosimetry calculation method to the imaging data collected to calculate tumor absorbed doses, using 3D-RD method.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Absorbed Dose</title>
        <description>Tumor absorbed doses (Gy) calculated using patient-specific dosimetry.</description>
        <time_frame>up to 4 years</time_frame>
        <population>Was only able to analyze tumor data from 3 patients based on number of tumors that could be reliably imaged for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patient-specific 3D-RD Dosimetry</title>
            <description>Applied a patient-specific dosimetry calculation method to the imaging data collected to calculate tumor absorbed doses, using 3D-RD method.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Absorbed Dose</title>
          <description>Tumor absorbed doses (Gy) calculated using patient-specific dosimetry.</description>
          <population>Was only able to analyze tumor data from 3 patients based on number of tumors that could be reliably imaged for analysis.</population>
          <units>Gy</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>number of tumors</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>number of tumors</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patient-specific 3D-RD Dosimetry</title>
          <description>Applied a patient-specific dosimetry calculation method to the imaging data collected to calculate tumor absorbed doses, using 3D-RD method.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The protocol was designed for data collection with minimal impact on treatment. Data collection was terminated due to low accrual . No reportable results could be obtained.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>George Sgouros</name_or_title>
      <organization>SKCCC</organization>
      <phone>4106140116</phone>
      <email>gsgouros@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

